BMY 28090

Known as: BMY-28090, BMY28090 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1989-2006
01219892006

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Elsamitrucin (BMY-28090) is an antitumor antibiotic first described in 1985 that has significant oncolytic activity against a… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
1997
1997
The aim of the present study was to identify the receptor subtypes involved in the alpha 1-adrenoceptor-mediated increase in 86Rb… (More)
Is this relevant?
1996
1996
Purpose: To determine the response rate of patients withrefractory/relapsed non-Hodgkin's lymphoma to treatment with elsamitrucin… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
1994
1994
Elsamitrucin (BMY-28090) a novel fermentation product has demonstrated pre-clinical anti-tumour activity against a number of cell… (More)
  • table 1
Is this relevant?
1993
1993
The cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human… (More)
Is this relevant?
1992
1992
Elsamitrucin (BMY-28090) is an antitumor antibiotic first described in 1985 that has significant oncolytic activity against a… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
1989
1989
BMY-28090 is a novel actinomycete fermentation derived antitumor agent. The cytotoxic effect of BMY-28090 was evaluated in two… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
1989
1989
The compound BMY-28090 (elsamicin A) is a new fermentation product with antitumor properties, which has the same aglycone as… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?